References

arthyper

Артериальная гипертензия

"Arterial’naya Gipertenziya" ("Arterial Hypertension")

1607-419X2411-8524

Antihypertensive League

10.18705/1607-419X-2012-18-6-514-521

arthyper-1736

Research Article

ОРИГИНАЛЬНАЯ СТАТЬЯ

ORIGINAL ARTICLE

ПЕРВИЧНЫЙ АЛЬДОСТЕРОНИЗМ И РЕЗИСТЕНТНАЯ АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ

Primary aldosteronism and resistant arterial hypertension

Звартау

Н. Э.

Zvartau

N. E.

nzvart@yahoo.com

Коростовцева

Л. С.

Korostovtseva

L. S.

noemail@neicon.ru

Емельянов

И. В.

Emelyanov

I. V.

noemail@neicon.ru

Свиряев

Ю. В.

Sviryaev

Yu. V.

noemail@neicon.ru

ФГБУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова» Минздрава РоссииРоссияAlmazov Federal Heart, Blood and Endocrinology CentreRussian Federation

2012

28122012

186514521

2012

Звартау Н.Э., Коростовцева Л.С., Емельянов И.В., Свиряев Ю.В.

Zvartau N.E., Korostovtseva L.S., Emelyanov I.V., Sviryaev Y.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://htn.almazovcentre.ru/jour/article/view/1736

В обзорной статье обсуждаются новые данные по первичному альдостеронизму, а также связь между повышением уровня альдостерона и резистентной артериальной гипертензией, в том числе и у пациентов с синдромом обструктивного апноэ во сне. Рассматриваются основные патофизиологические механизмы, лежащие в основе прогрессирования поражения органов-мишеней и формирования резистентности к антигипертензивной терапии при повышении уровня альдостерона.

The review discusses the new data about primary aldosteronism and the connection between increase of aldosterone level and resistance to antihypertensive treatment, including patients with obstructive sleep apnea. Also the main pathophysiological mechanisms underlying the progression of end organ damage and leading to resistance to antihypertensive treatment in patients with high aldosterone level are presented.

первичный альдостеронизмрезистентная артериальная гипертензиявоспалениеэндотелиальная дисфункцияфиброз

primary aldosteronismresistant hypertensioninflammationendothelial dysfunctionfibrosis

References1

Funder J.W., Carey R.M., Fardella C. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline // J. Clin. Endocrinol. Metab. - 2008. - Vol. 93, № 9. - Р. 3266–3281.

Lim P., Dow E., Brennan G., Jung R.T., MacDonald T.M. High prevalence of primary aldosteronism in the Tayside hypertension clinic population // J. Hum. Hypertens. - 2000. – Vol. 14, № 5. – P. 311–315.

Loh K., Koay E., Khaw M., Emmanuel S.C., Young W.F. Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore // J. Clin. Endocrinol. Metab. - 2000. – Vol. 85. № 8. – P. 2854–2859.

Mosso L., Carvajal C., Gonzalez A. et al. Primary aldosteronism and hypertensive disease // Hypertension. – 2003. – Vol. 42, № 2. – P. 161–165.

Rossi G., Bernini G., Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients // J. Am. Coll. Cardiol. – 2006. – Vol. 48, № 11. - P. 2293–2300.

Schwartz G., Turner S. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity // Clin. Chem. – 2005. – Vol. 51, № 2. – P. 386–394.

Ito Y., Takeda R., Karashima S. et al. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects // Hypertens. Res. – 2011. – Vol. 34, № 1. – P. 98–102.

Calhoun D.A. Is there an unrecognized epidemic of primary aldosteronism? (Pro) // Hypertension. – 2007. – Vol. 50, № 3. – P. 447–453.

Sukor N., Kogovsek C., Gordon R., Robson D., Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism // J. Clin. Endocrinol. Metab. – 2010. – Vol. 95, № 3. – P. 1360–1364.

Rossi G., Seccia T., Pessina A. et al. Primary aldosteronism — part I: prevalence, screening, and selection of cases for adrenal vein sampling // J. Nephrol. – 2008. – Vol. 21, № 4. – P. 447–454.

Douma S., Petidis K., Doumas M. et al. Prevalence of primary hyperaldosteronism in resistant hypertension:a retrospective observational study // Lancet. – 2008. – Vol. 371, № 9628. – P. 1921–1926.

Nishizaka M. K., Zaman M. A., Calhoun D. A. Efficacy of low-dose spironolactone in subjects with resistant hypertension // Am. J. Hypertens. – 2003. - Vol. 16, № 11. - P. 925–930.

Vasan R. S., Evans J. C., Larson M. G. et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons // N. Engl. J. Med. – 2004. - Vol. 351, № 1. – P. 33–41.

Bernini G., Galetta F., Franzoni F. et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism // J. Hypertens. – 2008. - Vol. 26, № 12. – P. 2399–2405.

Tsuchiya K., Yoshimoto T., Hirata Y. Endothelial dysfunction is related to aldosterone excess and raised blood pressure // Endocrine J. – 2009. - Vol. 56, № 4. - P. 553–559.

Tsioufis C., Tsiachris D., Dimitriadis K. et al. Myocardial and aortic stiffening in the early course of primary aldosteronism // Clin. Cardiol. – 2008. - Vol. 31, № 9. - P. 431–436.

Rossi G. P., Bernini G., Desideri G. et al. Renal damage in primary aldosteronism: results of the PAPY study // Hypertension. – 2006. - Vol. 48, № 2. – P. 232–238.

Milliez P., Girerd X., Plouin P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism // J. Am. Coll. Cardiol. - 2005. – Vol. 45, № 8. – P. 1243–1248.

Stowasser M. Sharman J., Leano R. et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I // J. Clin. Endocrinol. Metab. – 2005. – Vol. 90, № 9. – P. 5070–5076.

McAdam-Marx C., Ye X., Sung J. C.,. Brixner D. I. et al. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting // Clin. Ther. – 2009. - Vol. 31, № 5. – P. 1116–1123.

Logan A. G., Perlikowski S. M., Mente A. et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension // J. Hypertens. – 2001. - Vol. 19, № 12. – P. 2271–2277.

Cuspidi C., Macca G., Sampieri L. et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension // J. Hypertens. – 2001. - Vol. 19, № 11. – P. 2063–2070.

Muxfeldt E. S., Bloch K. V., Nogueira A. R. et al. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension // Blood Pres. Monitor. – 2003. - Vol. 8, № 5. – P. 181–185.

Pierdomenico S. D., Lapenna D., Bucci A. et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension // Am. J. Hypertens. – 2005. - Vol. 18, № 11. – P. 1422–1428.

Isaksson H., Ostergren J. Prognosis in therapy-resistant hypertension // J. Int. Med. – 1994. - Vol. 236, № 6. – P. 643–649.

Pratt-Ubunama M. N., Nishizaka M. K., Boedefeld R. L. et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension // Chest. – 2007. - Vol. 131, № 2. – P. 453–459.

Lavie P., Hoffstein V. Sleep apnea syndrome: a possible contributing factor to resistant // Sleep. – 2001. - Vol. 24, № 6. - P. 721–725.

Dernaika T.A., Kinasewitz G.T., Tawk M.M. Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea // J. Clin. Sleep Med. – 2009. - Vol. 5, № 2 - P. 103–107.

Lozano L., Tovar J. L., Sampol G. et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial // J. Hypertens. – 2010. - Vol. 28, № 10. – P. 2161–2168.

Di Murro A., Petramala L., Cotesta D. et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism // J. Renin Angiotensin Aldosterone Syst. – 2010. - Vol. 11, № 3. – P. 165–172.

Acelajado M.C., Calhoun D.A. Aldosteronism and resistant hypertension // Int. J. Hypertens. – 2011. – Vol. 2011. - Article ID 837817. doi: 10.4061/2011/837817.

Gaddam K., Pimenta E., Thomas S. et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report // J. Hum. Hypertens. – 2010. – Vol. 24, № 8. – P. 532–537.

Funder J.W. Mineralocorticoid receptors: distribution and activation // Heart Failure Rev. - 2005. – Vol. 10, № 1. – P. 15–22.

Boldyreff B., Wehling M. Aldosterone: refreshing a slow hormone by swift action // News Physiol. Sci. – 2004. – Vol. 19. – P. 97–100.

Liu S.L., Schmuck S., Chorazcyzewski J.Z., Gros R., Feldman R.D. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation // Circulation. – 2003. – Vol. 108, № 19. – P. 2400–2406.

Uhrenholt T. R., Schjerning J., Hansen P. B. et al. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone // Circ. Res. – 2003. – Vol. 93, № 12. – P. 1258–1266.

Arima S., Kohagura K., Xu H.L. et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole // Hypertension. – 2004. – Vol. 43, № 2. – P. 352–357.

Michea L., Delpiano A. M., Hitschfeld C., Lobos L., Lavandero S., Marusic E.T. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+-exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels // Endocrinology. – 2005. – Vol. 146, № 3. – P. 973–980.

Rocha R., Stier C.T.J., Kifor I. et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy // Endocrinology. – 2000. – Vol. 141, № 10. – P. 3871–3878.

Sun Y., Zhang J., Lu L., Bedigian M.P., Robinson A.D., Weber K.T. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart // J. Lab. Clin. Med. – 2004. – Vol. 143, № 1. – P. 41–51.

Brilla C.G., Weber K.T. Mineralocorticoidexcess, dietary sodium, and myocardial fibrosis // J. Lab. Clin. Med. – 1992. – Vol. 120, № 6. – P. 893–901.

Rocha R., Martin-Berger C.L., Yang P. et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart // Endocrinology. – 2002. – Vol. 143, № 12. – P. 4828–4836.

Rocha R., Chander P.N., Khanna K., Zuckerman A., Stier C.T. Jr. Mineralocorticoid blockadereduces vascular injury in stroke-prone hypertensive rats // Hypertension. – 1998. – Vol. 31, № 1, Pt. 2. – P. 451–458.

Han S.Y., Kim C.H., Kim H.S. et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats // J. Am. Soc. Nephrol. – 2006. – Vol. 17, № 5. – P. 1362–1372.

Chun T.Y., Bloem L.J., Pratt J.H. Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes // Endocrinology. – 2003. – Vol. 144, № 5. – P. 1712–1717.

Wahed M.I., Watanabe K., Ma M. et al. Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy // Pharmacology. – 2005. – Vol. 73, № 2. – P. 81–88.

Rocha R., Rudolph A.E., Frierdich G.E. et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart // Am. J. Physiol. Heart Circ. Physiol. – 2002. – Vol. 283, № 5. - H1802–H1810.

Okada H., Danoff T.M., Kalluri R., Neilson E.G. Early role of Fsp1 in epithelial-mesenchymal transformation // Am. J. Physiol. – 1997. – Vol. 273, № 4, Pt. 2. – P. F563–F574.

Ma L.J., Yang H., Gaspert A. et al. Transforming growth factor-β-dependent and -independent pathways of induction of tubulointerstitial fibrosis in β6−/− mice // Am. J. Pathol. – 2003. – Vol. 163, № 4. – P. 1261–1273.

Park J.B., Schiffrin E.L. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1 // Am. J. Hypertens. – 2002. – Vol. 15, № 2, Pt. 1. – P. 164–169.

Wong S., Brennan F.E., Young M.J. et al. A direct effect of aldosterone on endothelin-1 gene expression in vivo // Endocrinology. – 2007. – Vol. 148, № 4. – P. 1511–1517.

Guarda E., Katwa L.C., Myers P.R., Tyagi S.C., Weber K.T. Effects of endothelins on collagen turnover in cardiac fibroblasts // Cardiovasc. Res. – 2003. – Vol. 27, № 12. – P. 2130–2134.

Tostes R.C., Touyz R.M., He G., Ammarguellat F., Schiffrin E.L. Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats // J. Cardiovasc. Pharmacol. – 2002. – Vol. 39, № 6. – P. 892–900.

Pu Q., Neves M. F., Virdis A. et al. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling // Hypertension. – 2003. – Vol. 42, № 1. – P. 49–55.

Taddei S., Virdis A., Mattei P., Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension // Hypertension. – 1993. – Vol. 21, № 6, Pt. 2. – P. 929–933.

Nishizaka M.K., Zaman M.A., Green S.A., Renfroe K.Y., Calhoun D.A. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism // Circulation. – 2004. – Vol. 109, № 23. – P. 2857–2861.

Farquharson C.A., Struthers A.D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy // Clin. Sci. (Lond.). – 2002. – Vol. 103, № 4. – P. 425–431.

Romagni P., Rossi F., Guerrini L., Quirini C., Santiemma V. Aldosterone induces contraction of the resistance arteries in man // Atherosclerosis. – 2003. – Vol. 166, № 2. – P. 345–349.

Farquharson C.A., Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure // Circulation. – 2002. – Vol. 101, № 6. – P. 594–597.

Iglarz M., Touyz R.M., Viel E.C., Amiri F., Schiffrin E.L. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system // Am. J. Hypertens. – 2004. – Vol. 17, № 7. - P. 597–603.

Blanco-Rivero J., Cachofeiro V., Lahera V. et al. Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats // Hypertension. – 2005. – Vol. 46, № 1. - P. 107–112.

Calo L. A., Zaghetto F., Pagnin E. et al. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22phox in human mononuclear leukocytes // J. Clin. Endocrinol. Metab. – 2004. – Vol. 89, № 4. – P. 1973–1976.

Chun T.Y., Pratt J.H. Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes // Mol. Cell. Endocrinol. – 2005. – Vol. 239, № 1-2. – P. 55–61.

Fejes-Tóth G., Náray-Fejes-Tóth A. Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? // Endocrinology. – 2007. – Vol. 148, № 4. – P. 1502–1510.

Oestreicher E.M., Martinez-Vasquez D., Stone J.R. et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-l-arginine methyl ester-induced myocardial injury // Circulation. - 2003. – Vol. 108, № 20. – P. 2517–2523.

Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog // Hypertension. – 1994. – Vol. 24, № 5. – P. 571-575.

The authors declare that there are no conflicts of interest present.